MDM2 Protein: Target Overview, Research Applications, and Selection Guide

12 products

MDM2 (Mouse Double Minute 2) is a primary negative regulator of the tumor suppressor p53. As an E3 ubiquitin ligase, MDM2 promotes ubiquitination and proteasomal degradation of p53, and also inhibits p53 transcriptional activity by direct binding. MDM2 is frequently overexpressed in various cancers, including sarcomas, breast cancer, and leukemias, making it a high-priority target for anticancer therapy. Recombinant MDM2 proteins are essential tools for studying protein-protein interactions (MDM2-p53, MDM2-p14ARF), ubiquitination assays, and small-molecule inhibitor discovery (e.g., nutlin analogs).

MDM2 Target Overview

MDM2 is a nuclear E3 ubiquitin ligase with a well-defined N-terminal p53-binding domain, a central acidic domain, a zinc finger, and a C-terminal RING finger domain responsible for ubiquitin transfer. Key aspects of MDM2 biology include:

Binding to the transactivation domain of p53, blocking p53-mediated transcription
Ubiquitinating p53 at multiple lysine residues, targeting it for proteasomal degradation
Autoubiquitination and regulation of its own stability
Interaction with p14ARF (human) / p19Arf (mouse), which inhibits MDM2 activity and stabilizes p53
Regulation by oncogenic signaling (e.g., AKT phosphorylates MDM2 to enhance nuclear localization and activity)
Amplification or overexpression contributes to chemoresistance and poor prognosis in cancers

MDM2 also has p53-independent functions (e.g., regulating RB1, E2F1, and HIF-1α). Several splice variants exist (e.g., MDM2-ALT1), which may affect inhibitor binding and activity.

MDM2 Target Information

Target Name: E3 ubiquitin-protein ligase MDM2
Synonyms: MDM2, HDM2 (human), mouse double minute 2 homolog, p53-binding protein Mdm2
UniProt ID: Q00987
Target Class: E3 ubiquitin ligase; oncoprotein; p53 negative regulator

Key Research Applications of MDM2 Protein

Recombinant MDM2 is widely used in biochemical, biophysical, and cell-based studies, particularly those involving p53 regulation and ubiquitination.

Protein-Protein Interaction Studies

Study MDM2-p53 binding.
Analyze MDM2-p14ARF interaction.
Screen disruptor compounds that interfere with MDM2-mediated protein interactions.

Ubiquitination Assays

Reconstitute p53 ubiquitination in vitro.
Study MDM2 autoubiquitination.
Evaluate E1, E2, ubiquitin, ATP, and MDM2-dependent ubiquitin transfer.

Inhibitor Screening

Screen small-molecule inhibitors targeting the MDM2-p53 binding pocket.
Evaluate nutlin analogs and related p53-MDM2 disruptors.
Support high-throughput screening platforms.

Binding Kinetics

Measure MDM2-p53 interaction kinetics.
Characterize inhibitor affinity and mechanism.
Support SPR, BLI, ITC, ELISA, and fluorescence-based binding assays.

E3 Ligase Activity Assays

Measure ubiquitin transfer to p53.
Study MDM2 autoubiquitination.
Evaluate other substrates, such as RB1, where relevant.

Antibody Development and Validation

Validate MDM2 expression detection.
Support Western blot, IP, IHC, and antibody specificity studies.
Analyze MDM2 autoubiquitination or phospho-MDM2 markers.

MDM2 Experimental Workflows and Use Cases

Recombinant MDM2 proteins are most effective in functional and biochemical workflows:

AlphaScreen / TR-FRET – High-throughput screening for MDM2-p53 binding inhibitors
ELISA-based binding – Capture or competitive binding assays with p53-derived peptides (e.g., residues 15-29)
Ubiquitination reaction – In vitro reconstitution with E1, E2 (UbcH5 family), ubiquitin, and ATP
SPR / BLI – Kinetic studies of MDM2-p53 or MDM2-inhibitor interactions
Pull-down assays – Mapping interaction domains or validating compound target engagement
Cell-free degradation assays – Coupled ubiquitination-proteasome degradation of p53

Because MDM2 is an intracellular E3 ligase, it is not suitable for membrane-protein or receptor-ligand workflows. For activity assays, full-length MDM2 containing the RING domain is required for ubiquitination, but the N-terminal domain alone is sufficient for binding studies.

Browse Our MDM2 Products

Submit an inquiry or email inquiry@betalifesci.com for a customization request or bulk order quote.

Fast turnaround production is available at a affordable price point if none of our catalog products fits your desire specifications.

Filters

12 products

Sort

Sale

Human MDM2 (E3 Ubiquitin-Protein Ligase Mdm2) - Recombinant Protein

Molecule: MDM2;
Species: Human;
Expression system: E.coli;
Tag: N-6His;
Sequence: 1-218;

CAT#: BLT-08653P

Save $139

Sale

Human MDM2 (E3 Ubiquitin-Protein Ligase Mdm2) - Recombinant Protein

Molecule: MDM2;
Species: Human;
Expression system: E.coli;
Tag: N-6His;
Sequence: 1-491aa;

CAT#: BLT-07582P

Save $139

Sale

Mouse Mdm2 (E3 Ubiquitin-Protein Ligase Mdm2) - Recombinant Protein

Molecule: MDM2;
Species: Mouse;
Expression system: E.coli;
Tag: N-6His;
Sequence: 1-310aa;

CAT#: BLT-07180P

Save $139

Western blot analysis of extracts from 293 cells untreated or treated with Hydroxyurea using MDM2(phospho-Ser166) Antibody.

Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using MDM2(Phospho-Ser166) Antibody(left) or the same antibody preincubated with blocking peptide(right).

Rabbit anti-Human MDM2 Polyclonal Antibody

CAT#: BLC-05539A

Western blot analysis of extracts from HT29, Hela and 293 cells using MDM2(Ab-166) Antibody.

Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using MDM2(Ab-166) Antibody(left) or the same antibody preincubated with blocking peptide(right).

Rabbit anti-Human MDM2 Polyclonal Antibody

CAT#: BLC-05475A

Western blot analysis of extracts from SKOV3 cells, using MDM2 antibody.

Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using MDM2 antibody.

Rabbit anti-Human MDM2 Polyclonal Antibody

CAT#: BLC-05318A

IHC image of the antibody diluted at 1:50 and staining in paraffin-embedded human brain tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.57% DAB.

Phospho-MDM2 (S166) Recombinant Monoclonal Antibody

CAT#: BLC-06563A

Greater than 90% as determined by SDS-PAGE.

Recombinant Mouse E3 Ubiquitin-Protein Ligase Mdm2 (MDM2) Protein (His)

Molecule: Mdm2;
Species: Mouse;
Expression system: Yeast;
Tag: His;
Sequence: Full Length Protein;

CAT#: BLC-09729P

Online Inquiry

Recombinant Mouse E3 Ubiquitin-Protein Ligase Mdm2 (MDM2) Protein (His)

Molecule: Mdm2;
Species: Mouse;
Expression system: E.coli;
Tag: His;
Sequence: Full Length Protein;

CAT#: BLC-04682P

Online Inquiry

Recombinant Human MDM2 Protein (His Tag)

Molecule: MDM2;
Species: Human;
Expression system: E.coli;
Tag: His;

CAT#: BL-112PC

Online Inquiry

Recombinant Human MDM2 Protein

Molecule: MDM2;
Species: Human;
Expression system: E.coli;
Tag: GST;

CAT#: BL-1099SG

Online Inquiry

Recombinant Human MDM2 (1-118) Protein

Molecule: MDM2 (1-118);
Species: Human;
Expression system: E.coli;
Tag: His;

CAT#: BL-1032SG

Online Inquiry

How to Choose the Right MDM2 Protein

Selection depends on your experimental goal:

MDM2-p53 binding studies (inhibitor screening, ELISA, SPR)
Format: N-terminal domain (aa 1-120 or 1-150) – sufficient to bind p53 with high affinity
Focus: Untagged or small-tagged versions to avoid steric hindrance; biotinylation for plate-based assays

Ubiquitination assays (p53 ubiquitination or autoubiquitination)
Format: Full-length MDM2 containing an intact RING domain (aa 1-491)
Focus: Activity verification; E. coli-expressed MDM2 is active but lacks phosphorylation – acceptable for in vitro ubiquitination

Inhibitor mechanism studies (SPR, ITC)
Format: N-terminal domain or full-length (depending on inhibitor binding site)
Focus: High purity, monodispersity; confirm activity via binding to p53 peptide

Protein-protein interactions (MDM2-p14ARF)
Format: Full-length or N-terminal domain (ARF binds to the central region as well) – often full-length recommended
Focus: Use differently tagged versions for pull-down

Degradation assays (cell-free)
Format: Active full-length MDM2 + rabbit reticulocyte lysate or purified proteasome
Focus: Pre-formed MDM2-p53 complex; add E1/E2/ubiquitin

Antibody validation / Western blot controls
Format: Full-length recombinant MDM2 as positive control
Focus: Include known splice variants if needed

Common Pitfalls in MDM2 Research

Using only the N-terminal domain for ubiquitination studies – The RING domain is essential for E3 ligase activity; use full-length or at least aa 1-491.

Missing E2 enzyme selection – MDM2 works best with UbcH5b or UbcH5c in vitro; without the correct E2, ubiquitination efficiency is very low.

Ignoring autoubiquitination – MDM2 rapidly autoubiquitinates, which can deplete active protein over time; use fresh protein or include ubiquitin aldehyde / inhibitors.

Assuming all MDM2 inhibitors bind the p53 pocket – Some compounds target the RING domain or disrupt MDM2-p14ARF. Verify the mechanism.

Using bacterial MDM2 for phosphorylation-dependent studies – Bacterial MDM2 lacks phosphorylation; for Ser166 or Ser186 studies, use HEK293-expressed MDM2 or phospho-mimetic mutants.

When to Consider Custom MDM2 Proteins

Custom MDM2 constructs are often justified when:

Phosphorylated MDM2 (e.g., p-Ser166, p-Ser186) is required for mechanism studies

A specific splice variant (e.g., MDM2-ALT1) is needed

You require a different tag (no tag, Avi for biotinylation, or small His) for crystallization or SPR

Co-expression of MDM2 with p53 or p14ARF as a pre-formed complex is desired

Mouse MDM2 variants (e.g., with C462A mutation to abolish RING activity) are needed as negative controls

Need Help Selecting the Right MDM2 Protein?

If your project involves MDM2-p53 interaction studies, inhibitor screening, ubiquitination assays, p53 degradation pathways, or E3 ligase activity analysis, selecting the correct MDM2 domain, species, tag, and activity format is essential for reliable results.

We can help you:

Choose the most suitable MDM2 format, including N-terminal domain, full-length MDM2, RING domain, phosphorylated MDM2, RING-dead mutants, splice variants, or custom recombinant constructs.

Select the right MDM2 protein for binding assays, ubiquitination assays, inhibitor screening, E3 ligase activity analysis, antibody validation, or cell-free degradation workflows.

Optimize tags and labeling formats, including His, GST, MBP, SUMO, Avi-tag, biotinylated, or tag-free MDM2 proteins.

Match MDM2 protein design to MDM2-p53 binding, MDM2-p14ARF interaction, p53 ubiquitination, autoubiquitination, or phospho-MDM2 mechanism studies.

Troubleshoot weak p53 binding, low ubiquitination efficiency, excessive autoubiquitination, poor assay signal, tag interference, or E2 enzyme mismatch.

Develop custom MDM2 proteins tailored to your workflow, including phospho-mimetic mutants, RING-dead controls, pre-formed MDM2-p53 complexes, or species-specific variants.

Submit your project details for expert evaluation. Our technical team will review your application and recommend the most suitable MDM2 protein format for your research.

Qualified projects may be eligible for discounted or free samples for validation.

📧 inquiry@betalifesci.com 📞 +1(201) 888-7983

Contact Us Now for Inquiries, Orders, and Questions

MDM2 Protein: Target Overview, Research Applications, and Selection Guide

MDM2 Target Overview

MDM2 Target Information

Key Research Applications of MDM2 Protein

Protein-Protein Interaction Studies

Ubiquitination Assays

Inhibitor Screening

Binding Kinetics

E3 Ligase Activity Assays

Antibody Development and Validation

MDM2 Experimental Workflows and Use Cases

Browse Our MDM2 Products

Filters

Choosing The Right MDM2 Specifications for Your Research

How to Choose the Right MDM2 Protein

Common Pitfalls in MDM2 Research

When to Consider Custom MDM2 Proteins

Need Help Selecting the Right MDM2 Protein?